Molecular Diagnostics Market to Reach US$45.88 Billion by 2030
The global molecular diagnostics market was valued at US$18.17 billion in 2022 and is projected to reach US$45.88 billion by 2030, expanding at a CAGR of 12.3% from 2023 to 2030.
The global molecular diagnostics market is witnessing strong growth as healthcare providers increasingly adopt technologies capable of identifying disease-associated DNA and RNA sequences. According to The Insight Partners, the market was valued at US$18.17 billion in 2022 and is expected to reach US$45.88 billion by 2030, registering a CAGR of 12.3% during 2023-2030. The report also estimates an addressable market of approximately US$253.74 billion over the forecast period.
Molecular diagnostics are used across a broad range of clinical applications, including infectious diseases, oncology, genetic testing, cardiac diseases, and immune system disorders. The development of new diagnostic products, increasing demand for point-of-care testing, and the prevalence of diseases requiring accurate diagnosis are among the factors supporting market expansion.
Download Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00003124
Development of New Products Supports Market Expansion
Product innovation remains a significant factor shaping the molecular diagnostics market. Manufacturers are investing in new assays, kits, instruments, and diagnostic technologies designed to address evolving clinical requirements.
The report highlights several industry developments, including product launches and manufacturing expansions by companies such as Abbott, Siemens Healthineers, and Bio-Rad Laboratories. These activities demonstrate the continuing focus on expanding molecular and rapid diagnostic capabilities across healthcare markets.
The development of diagnostic technologies also supports broader applications in infectious disease testing, oncology, genetic analysis, and other clinical areas. As diagnostic platforms become more diverse, healthcare providers can deploy molecular testing across an expanding range of applications.
Rising Demand for Point-of-Care Testing Creates New Opportunities
Increasing demand for point-of-care testing is another important driver of the molecular diagnostics market. Point-of-care solutions can reduce the time associated with transporting and preparing clinical samples, potentially enabling healthcare professionals to make decisions more quickly.
The Insight Partners notes that point-of-care products are increasingly used across diagnostics, therapeutics, and patient monitoring. Their ability to support testing outside conventional laboratory environments has also increased interest in decentralized and at-home healthcare services.
The continued development of portable molecular testing platforms could therefore create opportunities for manufacturers seeking to expand molecular diagnostics beyond centralized laboratories.
Technological Advancements Expand Molecular Diagnostics Applications
Advancements in molecular diagnostic technologies are broadening the range of testing approaches available to healthcare providers. Molecular platforms can identify genetic changes and disease-associated sequences, including single nucleotide polymorphisms, deletions, rearrangements, and insertions.
The report highlights technologies such as reverse transcription loop-mediated isothermal amplification, microarray-based detection, aptamer-based diagnosis, SHERLOCK, biosensor-based approaches, and molecular imprinting among developments that have contributed to innovation in molecular testing.
PCR remains particularly important within the technology landscape. The report identifies Polymerase Chain Reaction as the technology segment expected to register the highest CAGR of 12.7% during the forecast period. PCR is further divided into RT-PCR, qPCR, multiplex PCR, and other approaches.
Infectious Disease Testing Remains a Major Application Area
Infectious disease represented the largest disease-area segment in 2022, accounting for 42.3% of the molecular diagnostics market. Molecular tests have become important tools for detecting infectious pathogens and supporting clinical decision-making.
The report also identifies oncology as an important growth area, with the oncology segment expected to register a CAGR of 12.6% during the forecast period. Molecular testing can support the identification and characterization of disease-related genetic and molecular changes relevant to cancer diagnosis and treatment planning.
The growing use of molecular techniques across both infectious disease and oncology applications is expected to contribute to continued market development through 2030.
Assays and Kits Drive Product and Service Opportunities
The product and services segment includes assays and kits, instruments, and services and software. Among these categories, assays and kits are expected to record the fastest growth, with a projected CAGR of 12.7% during the forecast period.
The expansion of assays and kits is closely connected with the increasing deployment of molecular testing across clinical laboratories, hospitals, research environments, and point-of-care settings. Demand for application-specific diagnostic solutions can encourage manufacturers to expand test menus and develop platforms for different disease areas.
Diagnostic Laboratories Represent a Key End User Segment
The molecular diagnostics market serves hospitals and clinics, diagnostic laboratories, research and academic institutions, and other end users. Diagnostic laboratories accounted for the largest end-user share in 2022, representing 39.9% of the market.
Diagnostic laboratories remain important environments for molecular testing because they provide the infrastructure, instrumentation, and technical expertise required for a wide range of molecular assays. At the same time, growth in point-of-care and decentralized testing is creating opportunities for molecular diagnostics outside traditional laboratory settings.
North America Leads While Asia Pacific Shows Strong Growth Potential
North America dominated the molecular diagnostics market in 2022 with a 44.3% share. The region includes the US, Canada, and Mexico and represents an important market for molecular testing technologies and diagnostic products.
The United States market is projected to grow at a CAGR of 12.7% during the forecast period. Meanwhile, Asia Pacific is expected to register a CAGR of 13.7%, reflecting significant growth potential across countries such as China, Japan, India, Australia, and South Korea.
The report also covers Europe, the Middle East and Africa, and South and Central America, providing analysis across major countries and regional markets.
Get Full Copy @ https://www.theinsightpartners.com/buy/TIPRE00003124
Market Segmentation
The molecular diagnostics market is segmented by disease area, technology, product and services, end user, and geography.
By disease area, the market covers oncology, infectious disease, genetic testing, cardiac diseases, immune system disorders, and others.
By technology, the market includes Polymerase Chain Reaction, isothermal nucleic acid amplification technology, DNA sequencing and Next-Generation Sequencing, DNA microarrays, in-situ hybridization, and others.
By product and services, the market is divided into assays and kits, instruments, and services and software.
By end user, the market includes hospitals and clinics, diagnostic laboratories, research and academic institutions, and others. Geographically, the study covers North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America.
Competitive Landscape
The molecular diagnostics market includes major life sciences, diagnostics, and healthcare technology companies. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Thermo Fisher Scientific Inc, bioMérieux SA, QIAGEN NV, Illumina Inc, Novartis AG, Agilent Technologies Inc, and TBG Diagnostics Limited.
Competition is shaped by product innovation, development of molecular testing platforms, expansion of diagnostic applications, point-of-care technologies, and efforts to address changing healthcare requirements.
Future Outlook
The global molecular diagnostics market is projected to expand from US$18.17 billion in 2022 to US$45.88 billion by 2030, representing a CAGR of 12.3%. The market’s development will be influenced by continued product innovation, growing demand for point-of-care testing, advances in PCR and other molecular technologies, and increasing applications across infectious disease, oncology, genetic testing, and other clinical areas.
North America is expected to remain an important regional market, while Asia Pacific is projected to record a higher growth rate during the forecast period. The continued evolution of assays and kits, molecular testing instruments, software, and decentralized testing models is expected to create further opportunities for market participants through 2030.
About Us
The Insight Partners, we provide comprehensive analysis and insights into market trends that empower businesses to make informed decisions. Our reports are designed to equip stakeholders with the necessary information to navigate the complexities of various industries, including healthcare, technology, and finance. We are dedicated to delivering high-quality research that enables our clients to achieve their strategic objectives.
Contact Us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : Korean German Japanese French Chinese Italian Spanish
